Gini Fleming to Carcinoma, Transitional Cell
This is a "connection" page, showing publications Gini Fleming has written about Carcinoma, Transitional Cell.
Connection Strength
0.033
-
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514.
Score: 0.033